ArticleBMC cardiovascular disorders2025
Effects of low-dose metoprolol succinate sustained-release tablets on patients with paroxysmal atrial fibrillation undergoing circumferential pulmonary vein isolation: a retrospective cohort study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Omics approaches to understand cardiovascular disease.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe atria, particularly those near the pulmonary vein ostium, have numerous autonomic neural plexuses. Circumferential pulmonary vein isolation (CPVI) can reduce heart rate variability (HRV) parameters. Studies have suggested that continuing antiarrhythmic drugs (AADs) for 1year post-CPVI can reduce the recurrence of atrial arrhythmias within the year. However, the arrhythmogenic risk associated with AADs is notable. Currently, there is a shortage of adequate studies on the effectiveness and safety of using AADs following CPVI. This exploratory study evaluated the impact of low-dose sustained-release metoprolol succinate on Holter in individuals with paroxysmal atrial fibrillation (PAF) after CPVI.
methodsPatients with PAF who underwent initialCPVI at Shaoxing People's Hospital between September 2022 and January 2024 were retrospectively enrolledusing the electronic medical record system. Patients underwent 24-h Holter monitoring before the procedureand at 1 - 3, 6, 12, and 18 months afterthe procedure. The participantswere separated into medication and non-medication groupsaccording to their heart rate and clinical experience.
resultsOverall, 67 patients completed the 24-h Holter monitoring, with 33 receiving low-dose metoprolol succinate (23.75 mg/day)(medication group) and 34 not receiving AADs (non-medication group). No significant differences were observed in HRV parameters and arrhythmia data between the two groups or across the different time points.
conclusionsOral low-dose sustained-release metoprolol succinate tablets may have no significant short-term effects on HRV parameters or arrhythmia data in patients with PAF post-CPVI. CPVI can cause autonomic dysfunction, and HRV parameters were gradually restored to normal 3months post-procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.